Azelastine/mometasone intranasal - Sandoz
Alternative Names: Mometasone/azelastine - SandozLatest Information Update: 11 Oct 2023
At a glance
- Originator Sandoz
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Azepines; Chlorinated hydrocarbons; Furans; Glucocorticoids; Ketones; Phenanthrenes; Phthalazines; Pregnadienediols; Skin disorder therapies; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists; Histamine H1 receptor antagonists; Mast cell stabilisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Seasonal allergic rhinitis
Most Recent Events
- 08 Sep 2023 Sandoz terminates a phase I trial in Seasonal allergic rhinitis (In adolescents, In adults) in Canada (Intranasal) as per the business decision (NCT05887843) (EudraCT2023-000362-34)
- 13 Jun 2023 Preclinical trials in Seasonal allergic rhinitis in Germany (Intranasal)
- 08 Jun 2023 Phase-I clinical trials in Seasonal allergic rhinitis (In adolescents, In adults) in Canada(Intranasal) (NCT05887843) (EudraCT2023-000362-34)